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Abstract: The collagenous dura mater requires a secure clo-
sure following implantation of neural prosthetic devices to
avoid complications due to cerebrospinal fluid leakage and
infections. Alginate was previously suggested for use as a
dural sealant. The liquid application and controllable gelling
conditions enable alginate to conform to the unique geome-
tries of a neural prosthetic device and the surrounding dura
mater to create a barrier with the external environment. In
this study, we evaluated the use of alginate as a method to
securely reclose a dural defect and seal around an untethered
microscale neural probe in the rabbit model. After 3 days and
3 weeks, the sealing strength of alginate remained eight
times greater than normal rabbit intracranial pressure and
similar in both the presence and absence of a penetrating
neural probe. For time points up to 3 months, there was no
significant difference in dura mater fibrosis or thickness
between alginate and controls. Application of alginate to a
dural defect results in a watertight seal that remains intact
while the dura mater reforms. These findings indicate that al-
ginate is an effective tool for sealing around microscale neu-
ral probes and suggests broader application as a sealant for
larger neural prosthetic devices. VC 2010 Wiley Periodicals, Inc.
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INTRODUCTION
The use of penetrating neural prosthetic devices in both the
research and clinical settings are increasing, necessitating
the development of advanced dural sealants and patches. A
watertight seal around these devices is imperative to pre-
vent cerebrospinal fluid (CSF) leakage or device failure due
to infection. A dural patch also functions to help keep the
surface of the brain moist, minimize swelling, and reestab-
lish the barrier to the outside world. A traditional dural
defect can be repaired by suturing a sheet of one of various
polymers1–5 or biologically occurring tissues6–12 to the sur-
rounding tissue. Unfortunately, these traditional approaches
are not appropriate for sealing around neural prosthetic
devices which must project through the dura mater and can
have smooth surfaces and unique geometries that prohibit
suturing.
An ideal duraplasty material for use with penetrating
neural prosthetics must satisfy several design requirements.
These include the following: (1) prevention of CSF leak-
age13–15 under increased intracranial pressure (ICP) condi-
tions which can be as high as 23 mmHg in humans follow-
ing significant brain trauma (2–3 times normal ICP)16; (2)
the seal with the surrounding tissue should be maintained
until the dura mater regrows5,15; (3) exhibit mechanical
properties similar to natural dura mater5; (4) not induce of
a harmful foreign body response17; (5) not cause any adhe-
sion formation between the dura mater and underlying cor-
tex,17 or prosthetic device; (6) not cause significant changes
in tissue morphology or function17; (7) easy to use; and (8)
not cause abnormal neuronal signaling or seizures.18
Historically, a variety of materials have been used for
duraplasty but many have had deleterious effects, including
leaks,14 seizure activity,19 hematomas,20 Creutzfeldt-Jakob
disease,21,22 and significant inflammatory response.1,2,13
More recently, the feasibility of using hydrogels to repair
dural defects has been demonstrated in animal models. Spe-
cifically, polyethylene glycol has demonstrated excellent
sealing capabilities and biocompatibility when used as a
dural sealant.23,24 Preliminary studies with alginate show
similar promise due to the long-term biocompatibility and
mild reaction conditions that allow hydrogel crosslinking
while in direct contact with the surrounding meningeal and
neural tissues.25,26 Additionally, alginate has been shown to
not cause seizure activity in rats25 or a significant inflamma-
tory response,27–30 problems which have hindered the de-
velopment of previous polymer-based dural sealants.19,31,32
There have been relatively few different approaches
employed to reseal a brain that has been implanted with a
penetrating neural prosthetic device. GelfoamV
R
, a hemostatic
absorbable gelatin scaffold, and Kwik-sil, a silicone silastic
polymer, have been commonly used.33–37 GelfoamV
R
has a
very mild inflammatory response which leaves little scaring
as the material degrades over 6 weeks. Silicone has been
shown to cause hematomas when used as a duraplasty ma-
terial in humans.20,38,39 Maynard et al. discussed a combina-
tion approach which employed a subdural Teflon sheet
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above the electrode array, and an epidurally sutured sheet
of PrecludeV
R
.40 While this approach prevented adhesion for-
mation between the dura mater and electrode array in
cats,40 PrecludeV
R
has been shown to cause osseous metapla-
sia after 6 months in rabbits.1 Additionally, both Teflon and
PrecludeV
R
require suture to hold them in place, creating
additional holes in the repaired dura mater and potential
for CSF leakage.
More recently, alginate has been described for dura-
plasty alone or in combination with penetrating neural pros-
thetic devices.26,41,42 Applied as a viscous liquid, alginate
does not require sutures to approximate the tissue or hold
the dural graft in place. This also allows alginate to form to
any shape, creating a seal around the unique geometries of
microelectrodes. Alginate’s ease of use, biocompatibility, and
sealing strength when used alone for duraplasty suggest it
is a superior candidate for resealing of the dura mater in
the presence of penetrating neural prosthetic devices.
The goals of this study were to investigate the following:
(1) the duraplasty sealing strength of alginate crosslinked
with CaCO3, (2) changes in tissue histopathology, and (3)
the sealing strength of alginate in the presence of a pene-
trating microscale neural probe in the context of a rabbit
duraplasty model. We sought to identify the interplay of al-
ginate degradation and tissue regrowth over time to under-
stand how these properties influence the sealing capabilities
of an alginate dural replacement patch. Additionally, we
wanted to identify tissue meningeal regrowth around the
probes over time to understand how these properties
potentially influence the sealing capabilities of an alginate
dural sealant in the presence of penetrating neural pros-
thetic devices. Ultimately, our goal was to demonstrate a
watertight seal around a penetrating neural prosthetic de-
vice and the ability of the hydrogel patch to maintain a bar-
rier against the external environment over time. The results
indicate that alginate is a viable dural replacement material




Hydrogel components, alginate and CaCO3, were prepared
and sterilized separately before use. Ultra pure sodium algi-
nate (43 mPas) was acquired from Novamatrix (Pronova UP
LVG, Drammen, Norway). Alginate was ethylene oxide gas
sterilized and a 1.95 wt % solution was made in sterile
water. The alginate solution was stored in sterile 1 mL ali-
quots for later use. CaCO3 (Sigma, St. Louis, MO) was
weighed out into 10 mg samples and ethylene oxide gas
sterilized.
The alginate and CaCO3 were mixed thoroughly before
application to the dural defect, resulting in a 100 mM
CaCO3 concentration. Glucono-d-lactone (GDL) (Sigma, St.
Louis, MO) was prepared into 1M solution in sterile water
and sterile-filtered immediately before use. The sterile GDL
solution was added to the alginate:CaCO3 solution at a final
GDL concentration of 80 mM and mixed vigorously. The
resulting three component mixture was allowed to sit for
10 min to increase solution viscosity to 400 cP,41 thereby
improving site-specific application of the hydrogel to the
dural defect and microscale neural probe. A volume of 20
lL was applied to the dural defect with a pipette.
Neural probe
The dummy neural probes were microfabricated from SU-8
and parylene-C, resulting in a transparent probe (Figure 1).
SU-8, a photoepoxy that is commonly used as a photoresist
in microfabrication processes, was used as the backbone of
the probe to provide rigidity during implantation. Parylene-
C was deposited on the SU-8 backbone at room temperature
to create the outer structures and a biocompatible isolation
barrier. Parylene-C has been employed as a biocompatible
insulating material on electrodes for many years and has
been shown to have no significant effect on the arachnoid
and pia mater after 16 weeks of implantation.43,44 These
materials were used in the probe construction because they
could be left in the tissue during sectioning to avoid disrup-
tion of the alginate:probe:dura mater interfaces.
Animals and groupings
New Zealand white rabbits (2.8–4.5 kg) were utilized (Har-
lan, Indianapolis, IN) to test duraplasty sealing strength and
biocompatibility of alginate alone and in the presence of a
penetrating microscale neural probe. In addition to alginate,
a hemostatic, absorbable gelatin scaffold (GelfoamV
R
, Phar-
macia & Upjohn, Kalamazoo, MI) was also investigated
alone. GelfoamV
R
was chosen because it is commonly used in
combination with penetrating neural prosthetic devices.36,37
Twenty-four rabbits were randomly assigned to an alginate
or GelfoamV
R
test group, before surgery, for experimental
endpoints of 3 days, 3 weeks, or 3 months. Each experimen-
tal condition and endpoint group consisted of four animals.
Upon completion of the initial experiments, six additional
rabbits were implanted with a neural probe before applica-
tion of the alginate for experimental endpoints of 3 days or
3 weeks (three animals each). All rabbits additionally
underwent a surgical control procedure. Every animal was
used for both identification of sealing strength and histol-
ogy. All procedures were approved by the University of
Michigan Committee on Use and Care of Animals.
Surgical procedure
Rabbits were initially anesthetized with an intramuscular
injection of ketamine (35 mg/kg) and xylazine (5 mg/kg)
followed by intubation for anesthesia maintenance with 2%
isoflurane. All animals were given a preoperative dose of
buprenorphine (0.05 mg/kg) to facilitate pain management
immediately following surgery. The scalp was opened with a
single midline incision and retracted, followed by the crea-
tion of bilateral, 1 cm diameter, calvarial defects posterior
to bregma. One defect was used for the sealing strength
experiment and the other one served as a control for the
tissue effects of bone removal. A 2-mm diameter duratomy
was performed in the middle of one of the calvarial defects.
For the alginate animals, alginate (20 lL) was applied as a
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highly viscous solution to the dural defect with a pipette. In
GelfoamV
R
animals, Gelfoam was applied using an in-lay tech-
nique, securing the GelfoamV
R
under the edges of the dura
mater surrounding the dural defect.45 For the alginate with
a probe condition, an untethered parylene-C neural probe
was placed centrally in the dural defect and subsequently
repaired with alginate as described earlier. After the dura
mater was repaired with alginate or GelfoamV
R
, both calvarial
defects were covered with a thin sheet of Teflon and cov-
ered with a bone cement headcap (TemPhase, sdsKerr, Swit-
zerland) secured to an anteriorly positioned bone screw for
structural rigidity. The skin was closed over the cement
with sutures and skin glue. All animals were given bupre-
norphine (0.05 mg/kg) postoperatively twice daily for 2
days following surgery to manage postoperative pain.
Sealing strength of dural patch
The ability of the dural patch to maintain a watertight seal
was tested at 3 days, 3 weeks, or 3 months postsurgery as
previously designated. To test the sealing strength, the rab-
bits were anesthetized as described for the initial surgery,
but were subsequently placed on mechanical ventilation
with 2% isoflurane for maintenance due to the prolonged
nature of the procedure. The rabbit’s midline incision was
reopened and continued caudally, exposing the neck muscu-
lature. The muscle tissue was removed to expose the occipi-
tal bones and the first cervical vertebra to yield clear access
to the cisterna magna. The bone cement headcap was dis-
placed to expose the calvarial defects and the duraplasty
site. Blood clots and bone tissue were carefully removed
from the calvarial defects as needed for clear visualization
of the duraplasty site containing the neural probe. A cathe-
ter was then inserted into the cisterna magna and glued
with a cyanoacrylate adhesive into place to prevent leaking
at the dura mater:catheter interface. Correct catheter loca-
tion was verified by rapid filling of the catheter with CSF.
The catheter was attached to a syringe pump (Model 55-
4155, Harvard Apparatus, Holliston, MA) and pressure
transducer (PX26-005DV, Omega, Stamford, CT) via intrave-
nous tubing.
The sealing strength was tested using methods adapted
by Filippi et al.7 Artificial cerebrospinal fluid (ACSF) with
0.05% carboxyfluorescein (Sigma, St. Louis, MO) was
infused at 0.05 mL/min under the control of a custom Lab-
View (LabView 7.1, National Instruments, Austin, TX) mod-
ule that controlled the syringe pump and recorded the infu-
sion pressure. This infusion rate was chosen because it is
greater than the normal rate of CSF formation for rabbits
(0.01 mL/min46) and insured accumulation of fluid volume
to continually increase ICP. Both the infusion volume and
pressure were monitored continuously by the LabView
module. The duraplasty/probe site was monitored with a
fluorescent stereomicroscope (MZ8, Leica, Switzerland) to
identify fluorescing on the surface of the brain and around
the neural probe and alginate hydrogel (Figure 2). Images
were collected with a CCD camera (SPOT 1.4.0, Diagnostic
Instruments, Sterling Heights, MI). ACSF with carboxyfluor-
escein was infused until leakage was detected visually or
until a pressure of 45 mmHg was exceeded. The leak pres-
sure was defined as the infusion pressure at which fluores-
cence was first detected on the surface of the alginate or
the surrounding dura mater. If the pressure exceeded 45
mmHg without rupture, the sealing strength was recorded
as 45 mmHg and the experiment was terminated. The
results for sealing strength were analyzed by a one-tailed
Mann-Whitney nonparametric t-test to identify significance
between time points.
FIGURE 1. A photomicrograph of the parylene-C neural dummy probe
with a SU-8 core. The probe is 3 mm long from the tip to top of head
and the shank width tapered from 170 lm wide to form the tip. The
main structure is 43 lm thick, but the lateral shank structure is only 5
lm thick. The probe has no recording sites and is not tethered to a
cable. [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
FIGURE 2. Visual detection of sealing strength after 3 weeks. A: A focal bump is seen where the dura mater has grown above the alginate and
neural probe. The location of the seal break is indicated by an arrow. The scale bar represents 2 mm in both micrographs. B: The fluorescence
micrograph indicates a leak. The leak corresponds to the left edge of the duraplasty indicated by an arrow in A. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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Tissue response
Upon completion of the sealing strength measurement, the
rabbit was exsanguinated under anesthesia via cardiac infu-
sion of 1 L of phosphate buffered saline followed by 1 L 4%
paraformaldehyde. After perfusion fixation was complete,
the brain was explanted in individual left and right hemi-
spheres, maintaining anatomical position of the tissues, and
postfixed in Bouin’s Fixative for 24 h. The samples were
dehydrated in a series of ethanol dilution rinses and paraf-
fin embedded. Serial sections, 6 lm thick, were taken over
the entire region of interest and stained with toluidine blue
(TB), hematoxylin and eosin (HE), or Masson’s trichrome
(MT). TB allowed for visualization of alginate within the
sample by staining the alginate purple. HE was used to
identify the presence of immune and inflammatory response
cells and level of fibrosis. MT clearly identified the menin-
geal tissue through the bright blue staining of collagen.
The level of fibrosis was determined using a predeter-
mined scale. One HE slide from the duraplasty site (alginate
or GelfoamV
R
) and control tissue of each animal was ana-
lyzed by three blinded observers and given a score (0–3).
The scoring levels indicating increasing levels of fibrosis are
as follows: (0) low fibroblast density in all meningeal tissue,
similar to naı̈ve tissue; (1) increased pial fibroblast density
but normal density in dura and arachnoid mater; (2)
increased fibroblast density in all layers of the meningeal
tissue; (3) dense fibroblast density in dura mater. The
scores reported by the blinded observers were combined to
calculate the average and standard error for each condition




Dura mater thickness was determined by measuring the
width of collagen in one MT stained slide from the dura-
plasty site or control tissue of each animal. The collagen
thickness was measured in four different places for each
sample and averaged resulting in a single thickness for each
sample. The thicknesses for a condition were combined to
calculate the average and standard error for each condition






The calvarial defects of all rabbits were reclosed by the 3-
month time point. On day 3, the calvarial defects were filled
with blood clots that could be easily removed to visualize
the alginate and neural probe. After 3 weeks, the blood clots
were replaced by a thin membrane that covered the calva-
rial defects. Although the neural probe could be clearly
identified surrounded by alginate on day 3, after 3 weeks,
the dura mater had grown over the alginate and neural
probe, impeding visualization [Figure 2(A)]. By 3 months,
the calvarial defects had completely filled in with new bone
tissue. Significant adhesions between the new bone and
underlying dura after 3 months was found on the dura-
plasty side in three of four GelfoamV
R
animals, but only one
of four alginate animals. No adhesions were detected in the
control calvarial defects.
Sealing strength of dural patch
Alginate demonstrated stronger sealing strength than
GelfoamV
R
(Figure 3 and Table 1). ACSF leakage was detected
visually as seen in Figure 2(B). On day 3, alginate withstood
significantly greater pressure than GelfoamV
R
(p < 0.01). Af-
ter 3 weeks, alginate continued to withstand significantly
greater pressure than GelfoamV
R
(p < 0.05). At the 3-month
time point, only two animals were tested per condition due
to adhesions or microtears of the dura mater due to bone
removal. The difference between the two materials was not
significant at this time point (p ¼ 0.34), although neither of
the alginate animals exhibited rupture whereas only one
GelfoamV
R
animal did not exhibit rupture. No significant dif-
ference in alginate’s sealing strength was detected between
the three time points (p ¼ 0.49). GelfoamVR , however, did ex-
hibit a significant increase in sealing strength over time
(0.31 mmHg/day, p < 0.01).
Alginate demonstrated excellent sealing capabilities in
the presence of the microscale neural probe (Figure 3 and
Table 1). On day 3, alginate withstood similar pressures in
the presence or absence of a neural probe. After 3 weeks,
alginate continued to withstand similar pressures in the
FIGURE 3. Duraplasty sealing strength was maintained over time for
alginate. Significance versus GelfoamV
R
at the comparable endpoint is
reported (* indicates p < 0.05, ** indicates p < 0.01). n ¼ 4 for 3 days
and 3 weeks, and n ¼ 2 for 3 months for alginate alone and
GelfoamV
R
. n ¼ 3 for all time points for alginate with probe.
TABLE I. The Sealing Strength of Alginate and Gelfoam
VR
3 Days 3 Weeks 3 Months
GelfoamV
R
5.83 6 2.09 14.01 6 3.34 33.98 6 11.03
Alginate alone 38.50 6 6.51** 33.52 6 6.85* 45.00 6 0.00
Alginate
with probe
43.33 6 1.67** 40.32 6 4.68* Not tested
Average pressures are reported in mmHg 6 standard error. Signifi-
cance versus GelfoamV
R
at the comparable endpoint is reported (*
indicates p < 0.05, ** indicates p < 0.01). n ¼ 4 for 3 days and 3
weeks, and n ¼ 2 for 3 months for alginate alone and GelfoamVR . n ¼
3 for all time points for alginate with probe.
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presence or absence of a neural probe. There was no signifi-
cant difference in the sealing strength between alginate
alone or in the presence of a dummy probe at either time
point (p > 0.50). Additionally, there was no significant
difference in the sealing strength between the two time
points in the presence of the microscale neural probe
(p ¼ 0.50).
Tissue response
No significant inflammatory response was seen for either al-
ginate or GelfoamV
R
. Changes in the tissue over time for both
experimental conditions are similar to that for control dura
mater.
Three days after duraplasty, both alginate and GelfoamV
R
were seen in close association with the underlying cortex
and surrounding dura mater. On both the control side and
test condition side (alginate or GelfoamV
R
), there were eryth-
rocytes present and the pia mater appeared thickened due
to a layer of fibroblast-like cells and an increased macro-
phage density. No significant increase in the fibroblast den-
sity (Figure 4 and Table 2) or thickening of the dura mater
(Figure 5 and Table 3) was detected above the normal
range at the 3 day time point. Dura mater repair was evi-
dent in both test conditions at the 3 week time point. New
dura mater was present both underneath and above the al-
ginate patch. GelfoamV
R
was surrounded by newly formed
dura mater and infiltrated with fibroblasts. All conditions
(alginate, GelfoamV
R
, and control) demonstrated an overall
increase in fibroblast density in all meningeal layers but
there was no significant difference between the conditions
(p ¼ 0.83 and 0.40 for 3 day and 3 week, respectively).
Dural thickness increased significantly for all conditions
between day 3 and 3 weeks (p < 0.05) but there was no
significant difference between conditions (p ¼ 0.73 and
0.24 for 3 day and 3 week, respectively).
No evidence of the dura mater repair patch (alginate or
GelfoamV
R
) remained at the 3 month time point. All condi-
tions (alginate, GelfoamV
R
, and control) showed evidence of
low-grade dural ossification on the newly formed and sur-
rounding dura mater but this finding was only focal to the
region of the calvarial defect. Granulation tissue could also
be seen at this time point. Distal dura mater appeared of
normal thickness and fibroblast density. In the region of the
calvarial defects and duraplasty, the level of fibrosis
decreased for both GelfoamV
R
and control but remained rela-
tively unchanged for alginate (Figure 4 and Table 2). The
thickness of the dura mater was similar in thickness to the
3 week time point, and remained significantly increased
over the 3 day time point (p < 0.05, Figure 5 and Table 3).
Paralleling the level of fibrosis, the dural thickness increase
was isolated to the region of the calvarial defect and rapidly
returned to baseline levels. No significant difference in fi-
brosis level (p ¼ 0.09) or dura mater thickness (p ¼ 0.64)
existed between the conditions at the 3 month time point.
FIGURE 4. Tissue fibrosis over time. There was no significant differ-
ence in the tissue fibrosis due to either alginate or Gelfoam
VR
com-
pared with the time-matched control. Average scores are reported 6
standard error, n ¼ 4 for alginate and GelfoamVR , and n ¼ 8 for
control.
TABLE II. Fibrosis Score
3 Days 3 Weeks 3 Months
GelfoamV
R
1.41 6 0.43 2.67 6 0.19 1.25 6 0.42
Alginate alone 1.00 6 0.36 2.00 6 0.41 1.92 6 0.08
Control 1.48 6 0.31 2.48 6 0.18 1.54 6 0.18
Average scores are reported 6 standard error, n ¼ 4 for alginate
and Gelfoam
VR
, and n ¼ 8 for control.
FIGURE 5. Dura thickness increased for all conditions (alginate,
GelfoamV
R
, and control) but there were no significant differences
between the conditions. n ¼ 4 for alginate and GelfoamVR , n ¼ 8 for
control.
TABLE III. Dura Mater Thickness
3 Days 3 Weeks 3 Months
GelfoamV
R
180.65 6 53.28 445.87 6 85.96 411.57 6 170.22
Alginate
alone
150.58 6 11.48 423.96 6 64.50 472.61 6 53.84
Control 151.68 6 17.39 569.20 6 54.35 399.61 6 61.34
Average thicknesses are reported in um 6 standard error, n ¼ 4 for
alginate and Gelfoam
VR
, and n ¼ 8 for control.
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Alginate remained immediately adjacent to the surface
of the neural probe up to 3 weeks. Three days after implan-
tation of the neural probe and alginate dura mater repair,
the alginate was seen in close association with the underly-
ing cortex, surrounding dura mater, and the neural probe
(not shown). Extensive dura mater repair was evident at
the 3 week time point (Figure 6). There was an overall
increase in fibroblast density in all meningeal layers com-
pared with the 3 day findings, and macrophages remained
present around the probe and alginate at 3 weeks [Figure
6(C)]. The increased fibrosis was also detected in the con-
trol dura mater. New, thickened dura mater exhibiting gran-
ulation grew above the alginate and neural probe to a thick-
ness of 486.99 6 148.54 lm, and there was evidence of
collagen production. The brain cortex appeared normal but
a mild gliosis was present at the pial interface. The pia
mater was also detectable following the probe shank into
the cortical tissue creating a thin layer of collagen between
the parylene-C probe and neural tissue [Figure 6(D)].
DISCUSSION
To investigate the use of alginate as a sealant around pene-
trating neural prosthetic devices, we identified the sealing
strength and biological response in the rabbit model. Appli-
cation of alginate to a 2 mm dural defect containing a pary-
lene-C intracortical neural dummy probe resulted in a
watertight seal around that probe, capable of withstanding
intracranial pressure elevated eight times over the normal
rabbit range. The dura mater reformed around the head of
the neural probe by 3 weeks, replacing the degrading algi-
nate. The results described herein indicate that alginate is a
suitable and desirable material for reestablishing a water-
tight barrier and allowing the dura mater to regrow in the
presence of penetrating neural prosthetic devices. This is
the first study that quantitatively identifies the strength of a
seal around an implanted neural prosthetic device.
Alginate demonstrated excellent sealing properties. A
possible explanation for the sealing strength of alginate is
surface tension between the edge of the dural defect and
FIGURE 6. Tissue response to alginate and parylene-C probe after 3 weeks. A: The probe (arrow) is seen in the middle of the micrograph sur-
rounding by alginate. The alginate has pulled away from both the tissue and probe due to dehydration of the sample during preparation. MT
staining allows visualization of the dura mater (blue) around the outer edge of the alginate (purple). The bar represents 400 lm. B: Alginate
stains bright purple with TB. Dura mater has grown above both the probe and the alginate patch. The bar represents 400 lm. C: The HE stained
section shows the increased fibroblast density in all layers of the meningeal tissue indicated by *. The bar represents 250 lm. D: The dura mater
grew above the implanted probe but the new dura mater is not fully formed as indicated by the lack of blue staining of collagen above the
probe. In this MT stained section, a 10 lm thick layer of collagen can be seen following the shank of the probe as it projects through the pia
mater into cortex (indicated by arrow). The bar represents 400 lm. In all micrographs: p, probe; a, alginate; c, cortex; and d, dura mater. [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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probe and the alginate. Using the cisterna magna infusion
method adapted by Filippi et al.,7 alginate was found to seal
as well as other commonly used duraplasty materials and
additionally maintain a watertight seal around the neural
probe that remained stable over time. This sealing strength
is comparable to other clinically used duraplasty materials
that close dural defects with no penetrating device.7,14,15
There was also no decrease in sealing strength due to the
presence of a neural probe. Furthermore, alginate does not
require suture or additional sealing with fibrin glue to
achieve a watertight seal around a neural probe. Together
these results indicate the advantages of alginate over other
approaches and satisfy the aforementioned design require-
ments: 1, 2, and 7.
An alginate dural patch retains a watertight seal over
time. Similar to Tutoplast dura, a solvent-dried cadaverous
human dura mater, the sealing strength decreased slightly
but not significantly between 3 days and 3 weeks.7 For the
alginate patch, this is possibly due to the slow degradation
of alginate before complete reformation of the surrounding
dura mater. Furthermore, the newly formed dura mater may
not be as strong as the original tissue. However, the sealing
strength was not significantly lower than the 3 day or
3 month time point, indicating that it still provides a water-
tight seal with the surrounding dura mater.
The alginate dural patch slowly degraded over time
while new dura mater grew above the parylene-C neural
probe. Histological investigation revealed that the dura
mater had reformed above the alginate and neural probe by
the 3 week time point, but the collagen staining was not as
dense as naı̈ve tissue. Despite this, the alginate patch was
able to maintain ICP eight times greater than normal pres-
sure for the rabbit. Because of the degradation of the algi-
nate patch, further investigation is necessary to determine
the sealing strength of alginate used to seal larger penetrat-
ing devices such as deep brain stimulating electrodes and
fluid shunts. These initial results are very positive however,
and support the continued use of alginate to seal around
neural prosthetic devices.
While this study included data from the dural patches at
3 months postduraplasty, we did not evaluate the alginate
dural patch in combination with the neural probe at this
time point. The initial experiments using alginate alone
showed that the alginate was fully degraded by the 3 month
time point. This finding indicates that the 3 month alginate-
probe data would not be indicative of the sealing strength
of alginate, but rather the strength of the newly formed
dura mater. While potentially interesting, this data is not
expected to be significantly different than that if no probe
was present, and therefore, in order to minimize the use of
animals, we omitted these treatments from the experimental
design.
These results for alginate are very similar to those for
another hydrogel used for dural repair, polyethylene glycol.
Previously, Preul et al. demonstrated that polyethylene gly-
col could be successfully applied to a 2 mm dural defect in
the canine model to generate a watertight seal.15,24 Despite
the use of suture to loosely approximate the dura mater in
the previous study,15 no obvious differences apparent
between the sealing strength of alginate and polyethylene
glycol. Similar to alginate, the sealing strength of polyethyl-
ene glycol slightly decreased over time, but both hydrogels
were able to maintain a watertight barrier over all tested
time points. To date, polyethylene glycol has not been tested
for its sealing capabilities in the presence of a neural pros-
thetic device.
The tissue response to alginate and GelfoamV
R
was very
mild. Typically, granulation tissue is found overlying the
dura mater following removal of the overlying calvarium.47
There was evidence of granulation tissue on the surface of
the dura mater at the 3 month time point, at which point,
extensive bone tissue remodeling had occurred in both con-
trol and experimental calvarial defects. Because of the inti-
mate relationship between dura mater and calvarium, this
development of granulation tissue is likely a natural
response to calvarial regeneration and remodeling.48 The
bone healing is probably also responsible for the low-grade
ossification seen at the 3 month time point in all dura mater
samples from the calvarial defect region. Unfortunately, the
relationship between the calvarium and dura mater during
the healing process is not fully understood and may also
contribute to the level of fibrosis and thickness of the dura
mater over time.49
The level of fibrosis seen in all three conditions peaked
at the 3 week time point and then decreased slightly by the
3 month time point. Because there is no difference in fibro-
sis between the conditions at any given time point, the
fibrotic response is most likely due to the removal of the
overlying calvarium and not a response to the alginate or
GelfoamV
R
. The peak of the fibrotic response at 3 weeks also
represents only a mild reaction that transitions into a low-
grade chronic fibrotic response of the tissue.50
At all three time points, dura mater thickness changes
were not significantly different between repaired dura
mater and control dura mater. Neither alginate nor
GelfoamV
R
contributed to the increases in dural thickness
seen in this study. Additionally, dura mater thickness for al-
ginate and a neural probe were similar to the alginate treat-
ment alone and determined to not have a significant effect.
The biggest contributing factor was opening the calvarium
and allowing the bone to heal. Hopper et al. reported simi-
lar dural thickening in rabbits receiving calvarial bone grafts
that were exposed to the underlying dura mater.49 This
same study also showed that a thin silicone isolation layer
between the dura mater and bone graft resulted in signifi-
cantly lower dural thickness increases.49 This suggests that
dural thickening increases for repaired dura could be con-
trolled via isolation of the dura mater from the overlying
bone or calvarial defect and supports our previous sugges-
tion to reposition the bone flap in the calvarial defect.
Untethered neural probes were used in this study to sim-
plify the experimental setup. Although a tethered probe
would offer a realistic condition, it would likely impede the
stability of the alginate:probe:tissue interface during removal
of the bone cement headcap. We surmised that this had
potential for destabilizing these interfaces during preparation
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for the sealing strength test, which would yield lower sealing
strength values than were actually occurring. For these rea-
sons, we chose to pursue an untethered neural probe
approach for this initial study. The high sealing strength val-
ues that we were able to measure in the short-term study (3
days) suggest that the alginate can maintain a watertight seal
around the probe and are therefore expected to perform the
same way in the presence of a tethering cable.
Because the alginate was still present around the neural
probe after 3 weeks, it is difficult to predict with certainty
if the dura mater would grow to become immediately adja-
cent to the probe to maintain the seal on its own. Histologi-
cal analysis revealed meningeal tissue following along the
shank as it penetrated into the cerebral cortex. Kim et al.
also found evidence of meningeal cells around their large
hollow fiber probes and suggested that materials in chronic
contact with meningeal tissue may serve as a bridging sub-
strate for the attachment, migration, and colonization of me-
ningeal-derived fibroblasts.51 This suggests that the dura
mater will eventually grow to develop a close contact with
the neural probe as the alginate degrades, satisfying the
aforementioned design requirements 4 and 6.
CONCLUSIONS
The use of an alginate hydrogel to seal around penetrating
neural prosthetic devices has many advantages over other
duraplasty methods. Here, we demonstrated that it can
securely withstand increased ICP levels when used to seal
around a penetrating microscale neural probe. As a single
material, it is less cumbersome than suturing a patch
around the probe followed by sealing with fibrin glue or
similar material. Applied as a liquid, the alginate hydrogel
can mold to the unique contours of the tissue and pros-
thetic device to create a watertight seal upon gelation. The
result of these synergistic properties is a novel dural sealant
with unique utility, facilitating an enhanced interface with
the surrounding meninges and providing a method to iso-
late the central nervous system after implantation of neural
prosthetic devices.
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